IBRN vs. IDNA
IBRN (iShares Neuroscience and Healthcare ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds from iShares - IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past 3 years, IBRN returned 11.10%/yr vs 6.48%/yr for IDNA. A 0.78 correlation means they provide meaningful diversification when combined. Both charge a 0.47% expense ratio.
Performance
IBRN vs. IDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IBRN achieves a 4.62% return, which is significantly lower than IDNA's 9.51% return.
IBRN
- 1D
- -4.52%
- 1M
- -1.90%
- YTD
- 4.62%
- 6M
- 12.73%
- 1Y
- 52.57%
- 3Y*
- 11.10%
- 5Y*
- —
- 10Y*
- —
IDNA
- 1D
- -2.18%
- 1M
- -2.18%
- YTD
- 9.51%
- 6M
- 10.53%
- 1Y
- 41.74%
- 3Y*
- 6.48%
- 5Y*
- -8.26%
- 10Y*
- —
IBRN vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
IBRN iShares Neuroscience and Healthcare ETF | 4.62% | 28.49% | -2.78% | 0.92% | 5.85% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 9.51% | 17.26% | -0.72% | -7.63% | -16.77% |
Correlation
The correlation between IBRN and IDNA is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.79 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.78 |
Correlation (All Time) Calculated using the full available price history since Aug 29, 2022 | 0.78 |
The correlation between IBRN and IDNA has been stable across timeframes, ranging from 0.78 to 0.79 - a consistent structural relationship.
IBRN vs. IDNA - Sectors Allocation Comparison
Sectors
IBRN
IDNA
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
IBRN
IDNA
Basic Materials
IBRN
-
IDNA
-
Communication Services
IBRN
-
IDNA
-
Consumer Cyclical
IBRN
-
IDNA
-
Consumer Defensive
IBRN
-
IDNA
-
Energy
IBRN
-
IDNA
-
Financial Services
IBRN
-
IDNA
-
Industrials
IBRN
-
IDNA
Real Estate
IBRN
-
IDNA
-
Technology
IBRN
-
IDNA
-
Utilities
IBRN
-
IDNA
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IBRN vs. IDNA — Risk / Return Rank
IBRN
IDNA
IBRN vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IBRN | IDNA | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.09 | 1.71 | +0.37 |
Sortino ratioReturn per unit of downside risk | 2.94 | 2.48 | +0.46 |
Omega ratioGain probability vs. loss probability | 1.34 | 1.28 | +0.06 |
Calmar ratioReturn relative to maximum drawdown | 6.30 | 4.09 | +2.21 |
Martin ratioReturn relative to average drawdown | 15.59 | 11.79 | +3.81 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IBRN | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.09 | 1.71 | +0.37 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.37 | 0.10 | +0.27 |
Drawdowns
IBRN vs. IDNA - Drawdown Comparison
The maximum IBRN drawdown since its inception was -35.38%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBRN and IDNA.
Loading charts...
Drawdown Indicators
| IBRN | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -35.38% | -68.26% | +32.88% |
Max Drawdown (1Y)Largest decline over 1 year | -8.80% | -10.66% | +1.86% |
Max Drawdown (3Y)Largest decline over 3 years | -35.38% | -29.73% | -5.65% |
Max Drawdown (5Y)Largest decline over 5 years | — | -68.26% | — |
Current DrawdownCurrent decline from peak | -6.28% | -46.01% | +39.73% |
Average DrawdownAverage peak-to-trough decline | -9.83% | -36.24% | +26.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.56% | 3.70% | -0.14% |
Volatility
IBRN vs. IDNA - Volatility Comparison
iShares Neuroscience and Healthcare ETF (IBRN) has a higher volatility of 7.66% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 7.24%. This indicates that IBRN's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IBRN | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.66% | 7.24% | +0.42% |
Volatility (6M)Calculated over the trailing 6-month period | 19.29% | 18.21% | +1.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.38% | 24.51% | +0.87% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.32% | 28.42% | -3.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.32% | 29.53% | -4.21% |
IBRN vs. IDNA - Expense Ratio Comparison
Both IBRN and IDNA have an expense ratio of 0.47%.
Dividends
IBRN vs. IDNA - Dividend Comparison
IBRN's dividend yield for the trailing twelve months is around 0.95%, less than IDNA's 1.08% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
IBRN iShares Neuroscience and Healthcare ETF | 0.95% | 0.99% | 0.40% | 0.06% | 0.00% | 0.00% | 0.00% | 0.00% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.08% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
Frequently Asked Questions
IBRN and IDNA have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IBRN has higher volatility (7.66%) compared to IDNA (7.24%). In terms of maximum drawdown, IBRN dropped -35.38% vs IDNA's -68.26%.
On 3-year performance, IBRN leads with 11.10% vs 6.48% for IDNA. Both ETFs have the same 0.47% expense ratio. On volatility, IDNA has been the lower-risk option at 7.24%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 3-year period, IBRN has performed better with a 11.10% return vs 6.48%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IBRN and IDNA have the same expense ratio: 0.47% per year.
IDNA has the higher dividend yield at 1.08%, compared with 0.95% for IBRN.
IBRN tracks NYSE FactSet Global Neuro Biopharma and MedTech Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index.
IBRN currently has the higher Sharpe Ratio (2.09 vs 1.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IBRN and IDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer